Compare TH & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TH | LXEO |
|---|---|---|
| Founded | 1978 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 669.5M | 731.3M |
| IPO Year | N/A | 2023 |
| Metric | TH | LXEO |
|---|---|---|
| Price | $7.30 | $7.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $11.00 | ★ $18.60 |
| AVG Volume (30 Days) | 329.2K | ★ 1.3M |
| Earning Date | 03-25-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $314,546,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.00 | $1.45 |
| 52 Week High | $10.12 | $10.99 |
| Indicator | TH | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 39.55 |
| Support Level | $6.70 | $6.73 |
| Resistance Level | $7.26 | $7.91 |
| Average True Range (ATR) | 0.22 | 0.47 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 49.30 | 40.00 |
Target Hospitality Corp is a vertically integrated specialty rental and hospitality services company in the United States. The company provides vertically integrated specialty rental and comprehensive hospitality services including catering food services, maintenance, housekeeping, grounds-keeping, on-site security, overall workforce lodge management, and laundry service. Its operating segment includes HFS-South and HFS-Midwest; Government; TCPL Keystone and others. It generates a majority of its revenue from the Government segment which consists of specialty rental and vertically integrated hospitality services revenue from customers with Government contracts located in Texas.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.